New Board and Council appointments signal ongoing commitment to thought leadership and development 17 June 2025, Johannesburg – The Mapungubwe Institute for Strategic Reflection (MISTRA), a South ...

A conversation on data from recent trials, lessons learned for future study, definitions and imaging protocols, how treatment can be refined, and more.

Intravenous thrombolysis in patients hospitalized for cervical artery dissection-related acute ischemic stroke increases the likelihood of home discharge.

A total of 25 patients at 24 hours and 17 patients at 7 days had both baseline and follow-up NIHSS scores of 1, which met the definition of major neurologic improvement; reclassifying these ...

Individuals with asymptomatic hemorrhaging infarction or subarachnoid hemorrhage after receiving endovascular treatment for acute ischemic stroke recorded worse 90-day recovery outcomes compared ...

Transplantation of neural stem cells improved neurologic and motor function for adults with chronic ischemic stroke at 12 months, according to a study presented at the International Stroke ...

Grants from the National Institutes of Health come with additional money for overhead. A planned $4 billion cut would leave colleges with large budget gaps. By Christina Jewett and Sheryl Gay ...

NIHSS is efficient and free, providing essential value to patients while optimizing clinical operations and resources. Data-Driven Results. The implementation of the dizziNIHSS initiative, ...

Every year, nearly 800,000 people in the United States have a stroke; of these approximately 610,000 are new strokes. 1 The approach to emergency stroke management (ESM) is widely researched, with ...

Symptomatic sICH was defined as any ICH with at least a four-point increase in the NIHSS score from baseline. The primary outcome was achieved in 33% of patients in the TNK group and 10% in best ...

The chance of a good functional outcome as marked by a modified Rankin Scale (mRS) score of 0-1 on day 90 was 50% improved with the neuroprotectant compared with placebo (64.4% vs 54.7%, OR 1.50 ...